Regnant Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 1.00 M
- Paid Up Capital ₹ 1.00 M
- Company Age 25 Year, 4 Months
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 1.17 M
- Revenue Growth 24.50%
- Profit Growth -6.06%
- Ebitda 8.41%
- Net Worth 5.18%
- Total Assets 1.57%
About Regnant Pharmaceuticals
Regnant Pharmaceuticals Private Limited (RPPL) is a Private Limited Indian Non-Government Company incorporated in India on 14 September 1999 and has a history of 25 years and four months. Its registered office is in Kamrup, Assam, India.
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 1.00 M and a paid-up capital of Rs 1.00 M.
The company currently has active open charges totaling ₹1.17 M.
Surjit Das and Biswajit Das serve as directors at the Company.
Company Details
-
Location
Kamrup, Assam, India
-
Telephone
+91-XXXXXXXXXX
-
Email Address
-
Website
-
-
Social Media-
Corporate Identity Details
-
CIN/LLPIN
U26921AS1999PTC005870
-
Company No.
005870
-
Company Classification
Private Limited Indian Non-Government Company
-
Incorporation Date
14 Sep 1999
-
Date of AGM
30 Sep 2023
-
Date of Balance Sheet
31 Mar 2023
-
Listing Status
Unlisted
-
ROC Code
Roc Shillong
Industry
Who are the key members and board of directors at Regnant Pharmaceuticals?
Executive Team (1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Biswajit Das
|
Managing Director | 14-Sep-1999 | Current |
Board Members (1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
|
Surjit Das
|
Director | 14-Sep-1999 | Current |
Financial Performance of Regnant Pharmaceuticals.
Regnant Pharmaceuticals Private Limited, for the financial year ended 2017, experienced significant growth in revenue, with a 24.5% increase. The company also saw a slight decrease in profitability, with a 6.06% decrease in profit. The company's net worth moved up by a moderate rise of 5.18%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
|
(FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
|
||||||
| Revenue from Operations |
|
||||||
| Total Assets |
|
||||||
| Profit or Loss |
|
||||||
| Net Worth |
|
||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Regnant Pharmaceuticals?
In 2017, Regnant Pharmaceuticals had a promoter holding of 70.00% and a public holding of 30.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
₹1.17 M
₹0
Charges Breakdown by Lending Institutions
- Dena Bank : 0.12 Cr
Latest Charge Details
| Date | Lender | Amount | Status |
|---|---|---|---|
| 04 Jan 2005 | Dena Bank | ₹1.17 M | Open |
How Many Employees Work at Regnant Pharmaceuticals?
Unlock and access historical data on people associated with Regnant Pharmaceuticals, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Regnant Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Regnant Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.